Stockwinners Market Radar for August 10, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:28 EDT Cathie Wood's ARK Investment bought 1.07M shares of Ginkgo Bioworks today

19:46 EDT Williams-Sonoma CEO sells $6.08M in common stock - In a regulatory filing, Williams-Sonoma disclosed that its CEO Laura Alber sold 40K shares of common stock on August 8th in a total transaction size of $6.08M.

19:15 EDT James Hardie names Anne Lloyd as successor to Michael Hammes as chairperson - James Hardie announced the appointment of Ms Anne Lloyd as successor to Michael Hammes as Chairperson. Ms Lloyd will immediately assume the role of Deputy Chairperson. Chairman of the Board, Michael Hammes, previously announced his intention to retire, and now plans to retire after the Company's November 2022 Board meeting and Annual General Meeting. Michael Hammes was elected as an independent non-executive director in February 2007, and he was appointed Chairman of the Board in January 2008. Commenting on Ms Lloyd's appointment, Mr Hammes stated, "Having served as Chairman of the James Hardie Board of Directors for over 15 years, it gives me great pleasure to be able to pass on this important role and responsibility to someone the caliber of Anne Lloyd. Anne has been on our Board for over three years and has operated within the industry for several decades. Her knowledge of James Hardie operations, the executive leadership team and the building materials industry make her an excellent choice to be the next Chairperson of James Hardie. Anne and I will work together over these next few months to fully transition the Chairperson responsibilities and expect to complete the succession process in early November 2022."

18:43 EDT Pan American Silver reports estimated mineral reserves, resources at June 30 - Pan American Silver reported its estimated mineral reserves and mineral resources as at June 30. Proven and probable mineral reserves are estimated to contain approximately 514.9M ounces of silver and 3.6M ounces of gold. Measured and indicated mineral resources are estimated to total approximately 838.6M ounces of silver and 8.1M ounces of gold. In addition, inferred mineral resources total 507.7M ounces of silver and 5.7M ounces of gold.

18:36 EDT Opthea Ltd (ADR) trading halted, news pending

18:25 EDT Quanterix director Walt acquires 150,000 common shares - In a regulatory filing, Quanterix director David Walt disclosed the purchase of 150,000 common shares of the company on August 10 at a price of $8.6233 per share.

18:15 EDT KKR director to buy $991K in common stock - In a regulatory filing, KKR disclosed that its director Matt Cohler bought 18.7K shares of common stock on August 8th in a total transaction size of $991K.

18:01 EDT Bausch Health to appeal XIFAXAN patent decision - Bausch Health and its gastroenterology business Salix Pharmaceuticals, announced that, consistent with the company's July 28 press release, the U.S. District Court of Delaware has issued a decision in the matter of Salix Pharmaceuticals, Ltd. et al v. Norwich Pharmaceuticals, Inc. finding certain XIFAXAN 550 mg HE patents valid and infringed and certain XIFAXAN composition and IBS-D patents invalid. As previously stated, the company will appeal this decision to the U.S. Court of Appeals for the Federal Circuit and it expects an appeal decision to issue within 12 to 18 months. To date, Norwich has not received tentative or final approval of its ANDA from the FDA. Unless and until FDA approves a revised Norwich ANDA that omits the XIFAXAN HE indication, and any injunction issued by the Court is modified, Norwich is not permitted to launch a generic equivalent of XIFAXIN.

17:45 EDT General Dynamics awarded $236.18M Navy contract modification - General Dynamics was awarded a $236.18M modification to a previously awarded contract for engineering, technical, design agent, and planning yard support for operational strategic and attack submarines. Work is expected to be completed by September 2023. FY22 other procurement funding in the amount of $5.55M will be obligated at time of award and will not expire at the end of the current fiscal year. The Naval Sea Systems Command is the contracting activity.

17:17 EDT Disney CEO says working hard to announce something on sports betting - In Q/A, CEO Bob Chapek says: "In terms of sports betting, we have been in conversations for quite a long time now with a number of different platforms to add some utility to sports betting and take away some friction for that for our guests. We have found that basically our sports fans that are under 30 absolutely require this type of utility in the overall portfolio of what ESPN offers. So we think it's important. We're working hard on it and we hope to have something to announce in the future in terms of a partnership there that will allow us to access that revenue stream and also make sure that our guests are being -- having their needs met."

17:04 EDT Fat Brands reaches agreement in principle to settle class action litigation - Fat Brands announced that it has reached an agreement in principle to settle the consolidated securities class action lawsuit captioned In re FAT Brands Inc. Securities Litigation, Case No. 2:22-cv-01820-MCS-RAO (C.D. Cal.), pending against the company and certain of its current and former officers and directors in the U.S. District Court for the Central District of California. The consolidated class action complaint was filed in March 2022, as described in the company's Annual Report on Form 10-K filed with the SEC on March 23. The agreement to settle the lawsuit was reached following a voluntary mediation process. The agreement in principle contemplates a cash payment by the company of $2.5M and issuance of $500,000 in Class A common stock to settle the claims brought on behalf of all persons who purchased or otherwise acquired FAT Brands securities between December 4, 2017 and February 18, 2022. The parties have agreed to negotiate in good faith to execute a definitive stipulation of settlement and related documents to be filed with the court. The company anticipates that the stipulation of settlement will provide a full release of all claims by the settlement class members against all defendants, including the company and the named officers and directors, and will expressly deny any liability, wrongdoing or responsibility by any of the defendants. The company anticipates that, upon final court approval of the settlement, the litigation will be dismissed with prejudice. Approval by the court, notice to the putative class, and the satisfaction of customary conditions to effectiveness may take several months. While FAT Brands continues to deny liability, it also believes that eliminating the distraction, expense and risk of continued litigation is in the best interests of the company and its stockholders. As previously disclosed, given the uncertainties of litigation, the company had not been in a position to assess the likelihood of any potential loss or outcome of the complaint. As a result of the entry into the agreement in principle, the company expects that the above-referenced settlement will be included in its results of operations and financial condition for the fiscal quarter ending September 25.

17:03 EDT Disney cuts FY22 capex by about $500M to $5.0B vs. $3.6B in FY21 - CFO Christine McCarthy says: "We are also revising our full year forecast for capital expenditures to $5 billion compared to fiscal 2021 CapEx of $3.6 billion. Our new expectation for 2022 is roughly $500 million lower than our previous guide, in part reflecting timing shifts of various projects across the company."

17:02 EDT Disney says content sales and licensing will continue to face headwinds - CFO Christine McCarthy says: "As we continue to scale back on third-party content licensing, we believe content sales, licensing and other results will continue to face headwinds and expect fourth quarter operating results will decrease versus the prior year by close to $100 million. Cash content spend across the company is now expected to total approximately $30 billion for fiscal 2022. This estimate is slightly lower than our previous guidance, largely due to timing changes and we expect annual cash content spend over the next couple of years to be roughly in the low $30 billion range as well." Comments taken from Q3 earnings conference call.

17:01 EDT Sonos drops 20% to $18.18 after cutting FY22 guidance, CFO change

16:57 EDT FingerMotion signs funding pact for $4M - FingerMotion is pleased to announce it has signed and closed a funding agreement for gross proceeds of $4.0 million New York-based institutional fund manager. "We are very pleased to have The Lind Partners as a significant FingerMotion investor," said Martin Shen CEO of FingerMotion. "The proceeds from this Investment will be primarily allocated across multiple high-margin and high-growth opportunity initiatives currently underway. In particular, the Company's highest priority initiative is the full-scale nationwide rollout of its mobile device protection business in China. This vertical is expected to yield the highest return on capital investment in the shortest amount of time, both strengthening our balance sheet and enabling us to experience transformational revenue growth over the next 12-24 months," CEO Martin Shen stated.

16:57 EDT Rani Therapeutics announces Study Part 1 of RT-102 achieves all endpoints - Rani Therapeutics announced topline results from the single-ascending dose portion of its Phase 1 clinical study of RT-102, a RaniPill capsule containing a proprietary formulation of human parathyroid hormone, or PTH, analog PTH for the potential treatment of osteoporosis. Study Part 1 achieved all of its endpoints, with RT-102 being generally well-tolerated and demonstrating high oral bioavailability of Rani's PTH analog. The single-center, open label, Study Part 1 of RT-102 was conducted in Australia. The study evaluated the safety, tolerability, and pharmacokinetics, or PK, of RT-102 in healthy adult female volunteers. Of the 39 participants, 15 were administered RT-102 containing a single 20 microgram dose of PTH and 14 were administered RT-102 containing a single 80 microgram dose of PTH, while a control group of 10 participants received a single 20 microgram subcutaneous injection, or SC, of Forteo, a commercial formulation of PTH for SC administration. The endpoints of the study were safety and tolerability, and measurements of serum concentrations of RT-102 in healthy adult female volunteers. RT-102 was generally well-tolerated, with no RaniPill-related adverse events, or AEs, observed in study participants: 0% of participants dosed with RT-102 20 microgram experienced drug-related AEs; 14% of participants dosed with of RT-102 80 microgram experienced drug-related AEs; 50% of participants dosed with 20 microgram of Forteo SC experienced drug-related AEs. There were no serious adverse events, or SAEs, noted during Study Part 1. Per protocol, in instances where the RaniPill capsule did not exit the stomach within seven hours, participants were excluded from the study. Based on the exclusion criteria, three participants were excluded from Study Part 1, one of whom experienced bloating, and one additional subject was excluded due to vomiting the capsule intact. In all instances, the capsule remnants passed from all participants who ingested the RaniPill capsule. Across our two clinical studies of the RaniPill platform, 81 subjects received the RaniPill capsule and no RaniPill-related AEs were observed in participants in the studies. Although the Study Part 1 did not include a head-to-head comparison with abaloparatide, RT-102 80 microgram demonstrated a PK profile similar to abaloparatide at 80 microgram as reported in the package insert for Tymlos. Two versions of the RaniPill were used during Study Part 1: Version C, which was used in Rani's Phase 1 study of octreotide and Version D, the latest iteration of the RaniPill. In addition to Study Part 1 of RT-102, the company also conducted a six-week pharmacodynamic, or PD, study of the RT-102 drug substance PTH to evaluate the effect of daily RT-102 DS intraperitoneal injections on bone mineral density in a rodent model of osteoporosis. The study compared two control groups of rodents undergoing sham surgery and ovariectomy receiving no drug, to three OVX groups each dosed with 5 mcg/kg per day of either RT-102 DS, teriparatide, or abaloparatide. The study found that, following six weeks of treatment: RT-102 DS increased BMD in a rat model of osteoporosis. RT-102 DS delivered via the RaniPill IP route of administration was biologically active comparable to SC injected PTH analogs.

16:49 EDT UMH Properties acquires South Carolina community for $5.2M - UMH Properties announced that it closed on the acquisition of a manufactured home community located in Orangeburg, South Carolina for a purchase price of $5.2M through UMH's newly formed qualified opportunity zone fund. This community contains 186 developed homesites, of which approximately 42% are occupied. It is situated on approximately 39 acres in a qualified opportunity zone.

16:42 EDT AppLovin drops 10% to $36.55 after reporting Q2 losses

16:39 EDT AppLovin drops 10% to $36.50 after cutting FY22 revenue guidance

16:34 EDT Gatos Silver evaluating material weaknesses in internal controls - Gatos Silver said: "The Company continues to advance efforts to produce an updated life-of-mine plan and update its mineral resources and mineral reserves. This update will incorporate information since the CLG mine commenced operation and will account for production mined through to June 30, 2022. The mineral resources and mineral reserves are being completely rebuilt from base data, including data compilation of surface drilling, underground drilling, underground mapping and production data, comprehensive data validation, structural and geological interpretation, resource estimation, reconciliation to actual production, and a new mine design including updates to operating and capital costs. The Company expects to produce a new CLG life-of-mine plan and technical report before the end of October 2022. The Company is also evaluating the material weaknesses in its internal controls over financial reporting related to the mineral reserve reporting errors. The Company's financial statements for the year ended December 31, 2021, and quarters ended March 31, 2022 and June 30, 2022, may be affected by the ongoing analysis."

16:33 EDT Wallbox acquires EV charging installation services company COIL - Wallbox announced that it has acquired COIL Inc, an EV charging installation service in the U.S. that will allow Wallbox to offer key partners including Auto OEMs, Utilities and Dealerships in North America a one-stop shop for EV installation and maintenance services. The acquisition highlights Wallbox's commitment to the North American EV charging market and follows the announcement of new warehouse facilities across the US and Canada. Wallbox also anticipates production to begin in their recently announced factory in Arlington, Texas this fall. "We are thrilled to bring the COIL team, their industry expertise and leading installation services into the Wallbox family," said Douglas Alfaro, General Manager North America at Wallbox. "This acquisition allows us to further enhance our service offerings to our customers in residential and commercial settings, while also expanding into the rapidly growing DC Fast Charging installation market."

16:32 EDT Landec sees FY23 Lifecore segment revenue $122M-$126M - Sees FY23 Lifecore segment adjusted EBITDA $31M-$32.5M.

16:30 EDT Archer Aviation sees Q3 adjusted operating expenses $63M-$71M

16:27 EDT Lifecore appoints James Hall as new CEO - Landec Corporation formally announced the Company's path forward as a CDMO-focused life sciences company, complete with a planned corporate rebranding, new ticker symbol, and the naming of its go-forward executive leadership team and Board of Directors. New CEO - The Board has appointed James Hall as its new Chief Executive Officer and to serve as a director on the Board of Directors, effective today. John Morberg, Landec's current Chief Financial Officer will continue on in his role and support the finance organization. Dr. Albert Bolles will serve as President of Curation Foods to oversee the remaining disposition activities related to the remaining Curation Foods businesses. Board Changes - In connection with this announcement, four members of the Board of Directors of the Company, Deborah Carosella, Tonia Pankopf, Andrew KPowell, and Catherine Sohn, have indicated that they will either step down or not stand for reelection to the Board of Directors at our next annual meeting in October of this year, which will create a life sciences focused Board of Directors with deep and diverse expertise, comprised of seven individuals.

16:26 EDT Victory Capital reports AUM of $164.2B as of July 31, 2022 - Victory Capital reported assets under management of $164.2B as of July 31, 2022. The company also reported average net assets under management for the month of July of $158.1B.

16:25 EDT Ceragon Networks issues statement on ISS recommendation against Aviat nominees - Ceragon Networks issued a statement with reference to a report issued by Institutional Shareholder Services or ISS in connection with the extraordinary general meeting scheduled to be held on August 23. The statement includes the following: "We are pleased that ISS recommends that shareholders vote AGAINST all of Aviat's nominees and echoes Ceragon's concerns regarding valuation and certainty. As stated in its report: '[Aviat's] offer lacks the certainty seen in typical M&A proxy contests. This is also a sizeable transaction for the bidder, so concerns regarding its ability to close are not completely unfounded...we note the [dissident nominees'] lack of public board and industry experience. The latter in particular seems very relevant'...ISS highlighted a number of significant concerns regarding Aviat's low-ball indication of interest, and the uncertainties around Aviat's ability to finance the transaction: 'The three analysts following the stock have target prices ranging from USD 4.00 to USD 6.00 per share, well above the offer price...' '"Key issues around certainty of the offer include financing commitment, breakup fees and deal conditions'...'Given turmoil in credit markets and the leveraged nature of potential deal, however, financing cannot be taken for granted'. ISS concludes that: '...a vote AGAINST all the dissident nominees is warranted.' We agree with ISS' recommendation to vote AGAINST all of Aviat's nominees. We believe that Aviat's nominees would leave Ceragon with a weak, inexperienced Board that will not be able to effectively oversee the Company's strategy or negotiate on behalf of Ceragon shareholders... As ISS states: 'It is in shareholders' best interests to encourage a hostile acquirer to submit an offer that is subject to as little conditionality as possible and is at an initial value sufficient to "earn" a seat at the negotiating table'."

16:23 EDT Red Robin reports Q2 SSS up 6.7% y/y and up 4.1% from 2019 - Q2 Restaurant level operating profit margin decreased by 210 basis points "driven primarily by commodity and wage rate inflation, partially offset by sales leverage and other labor costs". Paul J. B. Murphy III, CEO, said, "In the face of industry challenges and an uncertain macroeconomic environment, we are outpacing our peers with respect to comparable restaurant revenue and traffic as measured by Black Box Intelligence, and net value sentiment on social media channels. We attribute our relative out-performance to a continuation of our high-low value strategy which includes our successful premium limited time product promotions that drive average check, incremental margin and attachment, and compelling value promotions to attract market share, like our $10 Gourmet Meal Deal, that started in late June. With higher than expected commodity inflation during the second quarter, we implemented over two percent in pricing early in the third quarter to improve restaurant margins. Importantly, our guest satisfaction scores are rising, reflecting our back to basics operational execution, improved staffing, and declining team member turnover, that enable us to better serve our guests."

16:22 EDT Coinbase says received subpoenas from SEC regarding staking programs - In a regulatory filing related to its quarterly report, Coinbase stated: "The company has received investigative subpoenas and requests from the SEC for documents and information about certain customer programs, operations, and existing and intended future products, including the company's processes for listing assets, the classification of certain listed assets, its staking programs, and its stablecoin and yield-generating products. Based on the ongoing nature of these matters, the outcomes remain uncertain and the company cannot estimate the potential impact, if any, on its business or financial statements at this time. The company believes the ultimate resolution of existing legal and regulatory investigation matters will not have a material adverse effect on the financial condition, results of operations, or cash flows of the company. However, in light of the uncertainties inherent in these matters, it is possible that the ultimate resolution of one or more of these matters may have a material adverse effect on the company's results of operations for a particular period, and future changes in circumstances or additional information could result in additional accruals or resolution in excess of established accruals, which could adversely affect the company's results of operations, potentially materially."

16:20 EDT AllianceBernstein reports preliminary AUM $689B as of July 31 - Up from from $647B at the end of June. The 6.5% increase was driven by market appreciation and the July 1 acquisition of CarVal Investors, partially offset by firm-wide net outflows.

16:18 EDT Zivo says USDA claims regulatory jurisdiction for coccidiosis treatment - ZIVO Bioscience announced receipt of a letter from the U.S. Department of Agriculture's Center for Veterinary Biologics affirming that the agency has claimed jurisdiction for reviewing the Company's novel immune-modulating biologic for treating coccidiosis in broiler chickens. Coccidiosis is a parasitic disease of the intestinal tract caused by coccidian protozoa and is one of the largest health and animal welfare problems facing poultry flocks. The global poultry industry spends more than $1.5 billion annually on coccidiosis control, primarily using decades-old compounds that face growing anticoccidial drug resistance. Coccidiosis is a common disease for chickens, especially among young chicks, and can be fatal or result in compromised digestion. "I'm delighted with today's announcement that demonstrates ZIVO's commitment to advancing our product candidate toward commercialization and provides regulatory clarity. This jurisdictional decision is significant, allowing us to expedite our approval path. With regulatory jurisdiction now confirmed, we will advance discussions with the CVB on the final product development plan, regulatory strategy and data requirements for licensure. This clarity enables us to shape our path more concretely toward realizing our product's market potential," stated John Payne, Chief Executive Officer of ZIVO Bioscience.

16:18 EDT Axon names Brittany Bagley as new CFO and Chief Business Officer - Axon (AXON) announced that it has named Brittany Bagley as its new CFO and the newly created position of Chief Business Officer, effective September 26. Bagley replaces Jim Zito, who has been serving as interim CFO since May 4. Zito will resume his prior role as Senior Vice President of Accounting. Bagley joins Axon from Sonos (SONO), where she served as Chief Financial Officer, with oversight of financial, accounting, corporate development, investor relations, real estate, facilities organizations and the CIO and data organizations.

16:13 EDT UiPath names Brigette McInnis-Day chief people officer - UiPath announced that Brigette McInnis-Day is joining the Company in the role of Chief People Officer, effective September 2022. McInnis-Day is a former Google and SAP executive that brings more than two decades of enterprise software experience and will be responsible for leading strategy, execution, and vision at UiPath with a focus on acquiring and developing talent and shaping the culture to drive business. McInnis-Day joins UiPath most recently from Google, where she served as Vice President, Human Resources (HR) at Google Cloud. In that role, she led initiatives to attract and develop talent and to shape the culture for accelerated business growth and transformation globally. Prior to her role at Google, McInnis-Day worked as Chief Operating Officer of SAP SuccessFactors and held other senior executive HR roles, responsible for defining and implementing business strategies to drive sustainable growth, business operations, and ensure customer satisfaction across one of the world's largest HR cloud organizations. She also led SAP SuccessFactors' Digital HR Strategy and Transformation teams to promote forward-thinking HR strategies to optimize digital transformation in data platform and analytics.

16:12 EDT Disney says ad-supported Disney+ tier to launch in U.S. on December 8 - On December 8, Disney+ will introduce its ad-supported subscription offering in the U.S., the company announced. "With the launch, a new and comprehensive slate of subscription plans will be made available across Disney+, Hulu, ESPN+, and the Disney Bundle, giving viewers ultimate flexibility in choosing an option that suits their needs," Disney stated. "With our new ad-supported Disney+ offering and an expanded lineup of plans across our entire streaming portfolio, we will be providing greater consumer choice at a variety of price points to cater to the diverse needs of our viewers and appeal to an even broader audience. Disney+, Hulu, and ESPN+ feature unparalleled content and viewing experiences and offer the best value in streaming today, with over 100,000 movie titles, TV episodes, original shows, sports and live events collectively," added Kareem Daniel, Chairman, Disney Media & Entertainment Distribution. Disney+ Basic with ads will be priced at $7.99 a month, while Disney+ Premium with no ads will be priced at $10.99 per month or $109.99 annually.

16:10 EDT Disney reports Q3 Media and Entertainment Distribution revenue $14.11B - Disney reports Q3 Media and Entertainment Distribution revenue $14.11B, up 11% from a year ago. Reports Q3 Disney Parks, Experiences and Products revenue $7.39B, up 70% from a year ago. Direct-to-Consumer revenues for the quarter increased 19% to $5.06B and operating loss in DTC was ($1.06B). "Direct-to-Consumer revenues for the quarter increased 19% to $5.1 billion and operating loss increased $0.8 billion to $1.1 billion. The increase in operating loss was due to a higher loss at Disney+, lower operating income at Hulu and, to a lesser extent, a higher loss at ESPN+. Lower results at Disney+ reflected higher programming and production, technology and marketing costs, partially offset by increases in subscription revenue and, to a lesser extent, advertising revenue. The increase in programming and production costs was primarily due to more content provided on the service, including the impact of airing 64 IPL cricket matches in the current quarter compared to 29 matches in the prior-year quarter. Higher subscription revenue was due to subscriber growth and increases in retail pricing, partially offset by an unfavorable foreign exchange impact. The increase in subscribers as well as in technology and marketing costs reflected growth in existing markets and, to a lesser extent, expansion to new markets. Advertising revenue growth was due to the additional IPL matches in the current quarter. The decrease at Hulu was due to higher programming and production and marketing costs, partially offset by subscription revenue growth. The increase in programming and production costs was primarily due to higher subscriber-based fees for programming the Live TV service reflecting an increase in the number of subscribers, rate increases and the carriage of more networks. Subscription revenue growth was due to increases in subscribers and in retail pricing. Lower results at ESPN+ were due to higher sports programming costs, partially offset by an increase in subscription revenue due to subscriber growth," the company said.

16:08 EDT Manning & Napier reports preliminary AUM $19.3B as of July 31 - Compared with $18.5B at June 30.

16:05 EDT Energous says WattUp Powerbridge gets FCC Part 18 grant - Energous Corporation announced its new high-power WattUp PowerBridge transmitter has received U.S. Federal Communications Commission (FCC) Part 18 grant of equipment authorization for 15 watts of conducted wireless power transfer. The approval enables higher power transmission for the rapidly expanding Internet of Things (IoT) ecosystem, safely delivering higher levels of power, with no distance limitations to IoT and other connected devices such as electronic shelf labels and RF-based asset tracking. This new FCC certification follows recent global regulatory approvals received by Energous and increases the amount of power that can be transmitted wirelessly in the United States.

16:04 EDT Pear Therapeutics announces publication of insomnia analysis - Pear Therapeutics costs and insomnia severity for Somryst, the only FDA-authorized PDT for the treatment of chronic insomnia. Results showed clinically meaningful reductions in health-related services and costs in the 24-months after Somryst initiation compared to 24-months prior. Further, clinically meaningful reductions in ISI were also found at end-of-treatment at nine weeks compared to baseline. The retrospective analysis was published in the international peer-reviewed journal ClinicoEconomics and Outcomes Research. "These real-world data underscore the potential clinical utility and durable economic benefit of a prescription digital therapeutic like Somryst among people with chronic insomnia," said Yuri Maricich, M.D., Chief Medical Officer of Pear Therapeutics. "In the last 24 months, lack of sleep has been exacerbated by the ongoing COVID-19 pandemic and can greatly impact not only day-to-day activities, but also overall quality of life and long-term health. Now, it's especially important to examine digitally delivered treatment options that can address the underlying issues of chronic insomnia."

14:44 EDT SoftBank board approves transfer of Alibaba shares to finance subsidiaries - SoftBank (SFTBY) announced that its board of directors approved 1) the early physical settlement of prepaid forward contracts corresponding to a maximum of approximately 242M ADRs of Alibaba Group Holding Limited (BABA), an equity method associate of SBG, executed with several financial institution counterparties to raise funds using Alibaba shares held through several of SBG's wholly owned subsidiaries, and 2) the transfer of Alibaba shares to the Finance Subsidiaries in relation to the Physical Settlement. The Physical Settlement will take place sequentially at each Finance Subsidiary beginning in mid-August 2022, and is expected to be completed by the end of September 2022. SBG expects that the Physical Settlement of these prepaid forward contracts will not result directly in any additional sales of Alibaba shares at each financial institution counterparty into the market, as Alibaba shares subject to these prepaid forward contracts were hedged in the market at the time of the original monetization transactions by each financial institution counterparty. SBG expects that Alibaba shares beneficially owned by SBG will correspond to 14.6% following the Physical Settlement, a decrease from 23.7% as at the end of June 2022, of the total outstanding shares of Alibaba, which is a decrease below the 20% voting right holding ratio required to be deemed as an equity method associate.

14:26 EDT Martin Marietta raises dividend to 66c from 61c per share - Martin Marietta Materials announced that its board of directors approved an 8% increase in its quarterly cash dividend, raising it from 61c per share to 66c per share on the company's outstanding common stock. This dividend, which represents a cash dividend of $2.64 per share on an annualized basis, is payable September 30 to shareholders of record at the close of business on September 1. Ward Nye, Chairman, President and CEO, stated, "Today's announced dividend increase extends Martin Marietta's track record of delivering meaningful and sustainable dividends as a component of our balanced capital allocation priorities. Our strong financial position, free cash flow generation and durable, aggregates-led business model allow the company to prudently return capital to shareholders while continuing to invest in future growth opportunities to create superior long-term shareholder value."

13:41 EDT North American rail traffic down 0.7% for the week ending August 6 - The Association of American Railroads, AAR,reported U.S. rail traffic for the week ending August 6. For this week, total U.S. weekly rail traffic was 496,526 carloads and intermodal units, down 2.6% compared with the same week last year. Total carloads for the week ending August 6 were 230,573 carloads, down 1.6% compared with the same week in 2021, while U.S. weekly intermodal volume was 265,953 containers and trailers, down 3.4% compared to 2021. North American rail volume for the week ending August 6, on 12 reporting U.S., Canadian and Mexican railroads totaled 327,633 carloads, down 0.1% compared with the same week last year, and 354,967 intermodal units, down 1.2% compared with last year. Total combined weekly rail traffic in North America was 682,600 carloads and intermodal units, down 0.7%. Publicly traded companies in the space include CSX (CSX), Canadian National (CNI), Canadian Pacific (CP), Kansas City Southern (KSU), Norfolk Southern (NSC), Union Pacific (UNP),Trinity Industries (TRN), Greenbrier (GBX), FreightCar America (RAIL) and Wabtec ((WAB). Reference Link

13:30 EDT Altamira to divest, spin off legacy assets as focus shifts to RNA, CEO says

13:30 EDT Altamira Therapeutics CEO expects top-line data from COVAMID trial in Q4

12:09 EDT ReShape Lifesciences receives FDA 510(k) clearance for GIBI HD calibration tubr - ReShape Lifesciences announced it has received U.S. Food and Drug Administration 510(k) clearance for the disposable, Gastro Intestinal Balloon Indicator calibration tube for use in gastric and bariatric surgical procedures. The company expects U.S. commercial sales to begin in September 2022.

12:01 EDT CAE falls -14.0% - CAE is down -14.0%, or -$3.61 to $22.19.

12:00 EDT Centerra Gold falls -18.5% - Centerra Gold is down -18.5%, or -$1.14 to $5.02.

12:00 EDT Invitae rises 46.1% - Invitae is up 46.1%, or $1.05 to $3.34.

11:42 EDT SilverSun's SWK enters into strategic reseller agreement - SilverSun Technologies announced thats subsidiary, SWK Technologies, has entered into a strategic reseller agreement to provide an archiving and data assurance solution built on double blockchain technology. The solution will be marketed as Resilience powered by Sollensys. Resilience is specifically designed to ensure an indestructible and immutable copy of a company's critical data in case of cyber-attacks, for regulatory compliance needs, and for guaranteeing the data resiliency of a business continuity plan.

11:31 EDT Oracle announces renewal of strategic agreement with AT&T - Oracle (ORCL) announced it has renewed a strategic agreement with AT&T (T) that it said will help "give new capacity and capabilities for the company's database and application workloads running in Oracle Cloud." The new five-year deal will build on AT&T's use of Oracle Fusion Cloud Enterprise Resource Planning, Oracle Fusion Cloud Customer Experience, Oracle Cloud Infrastructure, and other Oracle Cloud services, the company stated. "AT&T is continually reinventing itself to better connect people and businesses, and we're proud to extend our partnership to support that connectivity. By using Oracle Cloud Infrastructure and Oracle Fusion Applications, AT&T is able to continue scaling globally and adapting to the evolving telecommunications market," added Jonathan Tikochinsky, executive vice president, strategic clients group, Oracle.

10:50 EDT Mace Security corporate controller Mark O'Conner departs - Mace Security International announced the departure of Mark O'Conner, who served as its Corporate Controller. Mark left the Company to pursue other interests.

10:49 EDT Mynaric selected for next phase of DARPA Program - Mynaric has been selected as a key development partner to create a benchtop model of a next-generation optical communications terminal as part of Phase 1 of the Space-based adaptive communications node program of the Defense Advanced Research Projects Agency. DARPA's Space-BACN program envisions a low-cost, scalable optical communications terminal that could be reconfigured to work with various optical intersatellite link standards allowing seamless communication among government and private-sector proprietary satellites. The announcement follows the selection of Mynaric to participate in the Space-BACN program's Phase 0 at the end of last year and represents Mynaric's continued success with U.S. government customers that are a driving force for the deployment of space-based, optical communication capabilities.

10:11 EDT AeroClean Technologies Inc trading resumes

10:06 EDT User reports indicate possble problems at Peloton, says Downdetector - Reference Link

10:01 EDT AeroClean Technologies Inc trading halted, volatility trading pause

10:00 EDT CAE falls -12.1% - CAE is down -12.1%, or -$3.13 to $22.67.

10:00 EDT Velo3D rises 24.9% - Velo3D is up 24.9%, or 89c to $4.46.

10:00 EDT Model N rises 29.3% - Model N is up 29.3%, or $7.67 to $33.86.

09:54 EDT MEGL Stock trading halted, volatility trading pause

09:50 EDT Intuit says Ben Chestnut to step back from role of Intuit Mailchimp CEO - Intuit announced that Ben Chestnut has made the decision to step back from his role as CEO of Intuit Mailchimp to take on a Business Advisor role within the organization. Rania Succar, a six-year veteran of Intuit and SVP of the QuickBooks Money Platform, will add the role of Intuit Mailchimp CEO to her responsibilities, the company announced. "I wanted Mailchimp to join Intuit so we could create one growth platform for small businesses everywhere. "I have always seen the potential for Mailchimp - an iconic brand which is loved all over the world - to win globally. I'm excited to ensure its continued success by making room for talented new leadership that will help our employees and our business soar to the next level," said Chestnut, who has led Mailchimp as CEO since co-founding the business 21 years ago.

09:47 EDT Cano Health falls -12.8% - Cano Health is down -12.8%, or -70c to $4.76.

09:47 EDT Nextdoor falls -13.3% - Nextdoor is down -13.3%, or -48c to $3.12.

09:47 EDT V2X rises 17.4% - V2X is up 17.4%, or $5.19 to $35.00.

09:46 EDT AMTD Digital Inc trading resumes

09:37 EDT Angies List trading resumes

09:32 EDT FleetCor to appeal ruling in FTC case - FleetCor Technologies announced that it will appeal the August 9, 2022 decision by the Northern District of Georgia regarding the Federal Trade Commission lawsuit involving its fuel card business in the U.S. While the court granted the FTC's motion for summary judgment as to liability for the company and its CEO, the court ruled in the company's favor denying the FTC's claim for monetary relief. FleetCor said it strongly disagrees with the ruling on liability, which the company believes was reached prematurely. It added: "Beginning in 2017, FLEETCOR voluntarily cooperated with the FTC and implemented enhanced disclosures addressing the concerns raised by the FTC. The Company has seen no material business impact or change in customer behavior as a result of these changes." "FLEETCOR takes governance and oversight matters seriously and is confident it has acted in accordance with all applicable laws," said Steven Stull, Lead Independent Director. "The Board fully supports the Company and Ron Clarke in their efforts to overturn this ruling."

09:32 EDT Angies List trading halted, volatility trading pause

09:27 EDT Bit Brother signs power lease agreement to launch blockchain business - Bit Brother, through its subsidiary in New York, Bit Brother New York, entered into a lease agreement with Petawatt Properties, a Wyoming limited liability company, which marks the initial step for the parties to jointly develop the cryptocurrency and blockchain business in North America. On August 2, Bit Brother New York and Petawatt entered into a lease agreement for a 22-acre plant in Carthage New York. Bit Brother New York agreed to pay Petawatt an annual rent of $1M for a term of ten years which could be deducted from the purchase price if Bit Brother acquires majority equity interest of Petawatt. Petawatt agreed to secure power supply agreements for 62.5MW of green power by September 1. Otherwise, Bit Brother New York may terminate the lease and Petawatt shall return the $100K deposit it received If fully operational with 62.5 MWs of power supply, the plant is expected to host 17,800 mining rigs with the hash rate of 110TH assuming average hash power of 3.5kw/h per miner.

09:20 EDT NovAccess announces uplisting to OTCQB - NovAccess Global announced that the trading of its common shares has been upgraded to the OTC Markets Group's OTCQB platform from the OTC Pink Market. The Company's ticker symbol remains the same.

09:17 EDT NextNav appoints Subin as new board member - NextNav (NN)announced that Neil Subin has joined the company's board of directors effective today. Subin replaces Peter Barris, who was recently named Chairman of the Board of Trustees of Northwestern University. Subin currently serves as Chief Investment Officer for MILFAM, a single-family office. Subin currently serves on the boards of Alimco Financial, Centrus Energy Corp (LEU), Frontiersman, and Quantlab Financial

09:14 EDT AmpliTech forms new TGSS division to offer managed communications as a service - AmpliTech Group announced the formation of AmpliTech True G Speed Services, TGSS. AmpliTech Group TGSS division was formed to enable "true G speeds" by providing Open Radio Access Network compliant Open Radio Units, and complete system integration for telco customers, enabling 'True G Speeds' to the industry. TGSS will design and develop these 5G radios on base station towers and will serve them to optimize the 5G ORAN compliant interface for adapting 5G systems for customers in the telecom space. TGSS will manage the transition for carriers to integrate new 5G radios and commission them for ORAN 5G compliance, 5G planning, and optimization of networks and architecture. Fawad Maqbool, Founder, and CEO of AmpliTech Group state "TGSS has always been a part of our vision for the AmpliTech brand. We see today that communication systems do not achieve the data transmission performance and reliability that 5G should deliver. AmpliTech Group has operated strategically over the past few years to produce the building blocks needed to provide high-quality RF components to enable unmatched signal quality in communication systems. Our existing units work to build the amplifiers and system components, and now TGSS will package these industry-leading solutions across 5G and eventually 6G, to leverage the expertise of our talented engineering team and offer a world-class solution that can be adopted by the customer directly." Maqbool continued, "Together with the combination of our industry-leading components, end-to-end servicing of the full system, and performance monitoring, we will reduce the integration burden customers have when implementing their systems while boosting performance and decreasing their overall cost of deployment and maintenance. We feel that this is an immensely compelling value add for our customers, and I am excited to take this step closer to realizing our mission of providing the communication systems of tomorrow, today."

09:12 EDT Udemy, Benesse, the Tokyo Metropolitan Government offer education in Tokyo - Udemy together with Benesse, its long-time partner in Japan, announced a new program with the Tokyo Metropolitan Government to accelerate the digital transformation of small and medium-sized enterprises, SMEs, in Tokyo. In collaboration with the Tokyo Metropolitan Government, Udemy and Benesse will support SME growth by providing the relevant courses on core emerging technologies and skills. By March 31, 2023, Udemy and Benesse aims to provide up to500 employees from 250 SMEs located in Tokyo curated education plans to develop various skills needed to drive digital transformation. "Markets and business environments are changing rapidly these days, and digital transformation is an important opportunity for Japanese companies," said Chie Omiya, head of Udemy Business for Government, Benesse. "We've worked with more than 800 organizations in Japan in the past, and we are pleased to support SMEs in Tokyo with their learning and reskilling goals alongside the Tokyo government. Udemy and Benesse continue to provide a wide range of courses on cutting-edge skills to help companies and municipalities develop DX skills and solve business challenges."

09:09 EDT Teladoc Health makes A1C testing easier for members with diabetes - Teladoc Health announced the addition of a home A1C testing program to its Livongo by Teladoc Health chronic care solution, making it easier for members to manage and control their diabetes. Livongo by Teladoc Health members will have the option to receive at-home A1C tests provided by LetsGetChecked. The announcement comes as new company data shows that 58% of members opt for the at-home service when given the chance, with a three to four times greater consumer test return rate than other options on the market. Coupled with the Livongo by Teladoc Health diabetes management program and whole-person integrated programs to address hypertension, weight, mental health and other frequent comorbidities, 87% of members using the in-home test reported a controlled A1C of 8% or less. "Meeting people where they are is paramount for enabling better clinical outcomes," said Vidya Raman-Tangella, chief medical officer at Teladoc Health. "Social and environmental factors account for 50-60% of health, and we are addressing persistent challenges by offering in-home testing. The data gathered by giving more people necessary tools will help us to create actionable insights that fuel a more individualized approach to health care."

09:08 EDT WidePoint unit ITA awarded new MSP contract valued at $2.6M - WidePoint announced that its subsidiary IT Authorities has been awarded a new Managed Service Provider contract by a leading U.S. beverage bottler. The contract is for three years with a total contract value of $2.6M. Jason Caras, CEO of IT Authorities, stated: "ITA has been working on a month-to-month basis with this bottler for a long time. This new three year Managed Services contract award is a result of our past performance of superior service delivery, and the ability for ITA to offer expanded services through WidePoint. We are honored to work with this industry leader."

09:07 EDT Biora Therapeutics announces successful completion of device performance study - Biora Therapeutics announced topline results from its recently completed study PM-602: A Scintigraphic Study to Evaluate the Localization and Delivery Function of a Drug Delivery System Capsule, DDS, in Subjects with Ulcerative Colitis in a Fasted State. The study demonstrated that the device was well tolerated, and that the device performed as intended in active ulcerative colitis, UC, patients. In all seven patients, the device accurately identified entry into the colon, triggered release of a liquid payload, and achieved distribution across the entire colon. "We have now completed three successful device function studies in humans that support the safety profile and performance of our targeted therapeutic device, in active UC patients and in healthy patients in both fed and fasted states," said Adi Mohanty, Chief Executive Officer of Biora Therapeutics. "These human studies are key steps in advancing toward our PGN-600 clinical program, and they also demonstrate the potential of the platform for localized delivery of other drugs." During the PM-602 study, Biora's device was ingested orally by seven patients with active ulcerative colitis in a single dosage event. After identification of colon entry, the device released a saline solution payload that included radioisotopes. Serial gamma-scintigraphy images were used to independently determine device localization and payload delivery to the lower gastrointestinal tract. No investigational drug was administered during the study. More information on the PM-602 study will be released as analysis is completed and submitted for publication.

09:06 EDT Identiv reports 41% y-o-y growth in RFID business - Identiv reported radio frequency identification - RFID - revenue for its transponder business up 41% year-over-year in the quarter. Identiv is on track to expand its RFID team in sales, product, engineering, and operations through 2023. The company's Singapore location has expanded RFID product demand capacity to meet 350M+ units and expects to open a second operations facility in Southeast Asia to increase volume substantially beginning in 2023.

09:05 EDT Electronic Arts renews multi-year partnership with NFL for MCS - Electronic Arts and the National Football League, or NFL, revealed a new multi-year partnership renewal for the EA Sports Madden NFL Championship Series, or MCS. The agreement will help align MCS with NFL events and key moments throughout the season. The NFL and EA will elevate Madden NFL competitors into stars, using creative, humanizing storytelling to entertain Madden and football fans alike. To maximize reach and fan engagement, the recently announced MCS 23 calendar will closely align with the NFL season, culminating with the Ultimate Madden NFL 23 Bowl during the week of Super Bowl LVII, as $1.7M in total prize money is up for grabs throughout the season. The NFL and EA will partner on new experiences to provide fans around the world with more ways to connect with the excitement of NFL football.

09:02 EDT Hagerty to acquire Broad Arrow Group for $64.8M in an all-stock transaction - Hagerty announced that it has entered into a definitive agreement to acquire all outstanding shares of Broad Arrow Group, which specializes in the transactional segments of the collector car market. Earlier this year, Hagerty acquired approximately 40% equity ownership in Broad Arrow Group as a centerpiece of its automotive Marketplace strategy, designed to provide consumers new trust-based platforms for buying, selling and financing collectible cars. Hagerty is now acquiring the remaining 60% of Broad Arrow for $64.8M in an all-stock transaction, with an expected closing date of August 16.

08:52 EDT CSP Inc. board reinstates quarterly dividend of 3c per share - The Company announced that its Board of Directors has reinstated and declared a quarterly dividend of $0.03 per share, payable on September 9, 2022, to CSPi shareholders of record on the close of business on August 22, 2022

08:47 EDT RT Mosaic to join Focus partner firm Cardinal Point - Focus Financial Partners announced that it has entered into a definitive agreement under which RT Mosaic Wealth Management will join Focus partner firm Cardinal Point Capital Management ULC. This transaction is expected to close in the third quarter of 2022, subject to customary closing conditions. Founded in 2010 by Chris Rawles and Spencer Tilley, RT Mosaic is an integrated wealth management firm located in Calgary, Alberta. It provides financial planning and investment advisory services to high net worth individuals and families. This transaction will provide RT Mosaic with expanded operational and service capabilities, as well as deepen and broaden the client service capabilities of the combined firm. Through this transaction, Cardinal Point will expand its footprint in Calgary and benefit from adding two tenured advisors to its leadership team.

08:42 EDT Jack in the Box lowers restaurant level margin view to~16%, from previous ~17% - Overall Jack in the Box restaurant level margin is now expected to be ~16%, previously ~17%, which includes high single-digit price increases.

08:40 EDT Jack in the Box lowers FY22 company-wide CapEx to $50-$55M from $75-$80M - Company-wide CapEx & Other investments guidance now $50-55M, previously $75-80M, due primarily to lower franchise incentive capital deployment toward restaurant reimages

08:39 EDT Surgalign enter global settlement agreement with Resolve Surgical, RTI Surgical - Surgalign announced that effective August 5, 2022, the Company entered into a global settlement agreement with Pioneer Surgical Technology d/b/a Resolve Surgical Technologies and RTI Surgical, relating to the sale of its OEM business in 2020 and the continued relationship the Company has had with RTI since. As part of the settlement, the parties have amended various agreements, including the distribution agreements for spinal implants and biologics. As per the terms of the agreement, all parties have settled the litigation and released each other from potential claims. The amendments released Surgalign from the obligation to cure a purchase shortfall for the current year and reduced the minimum annual purchase requirements. In addition, the sole-source relationship has been extended for an additional two years with updated supply chain provisions reflecting the separation of Surgalign and Resolve/RTI. "We are pleased to settle the dispute with Resolve and RTI and look forward to the future business our companies can do together," said Terry Rich, President and CEO of Surgalign. "The negotiations gave us the opportunity to work through post-split issues that we identified over the past two years, following separation. The newly amended contracts are a better fit for our ongoing relationship and our current business."

08:38 EDT Ideal Power delivers initial B-TRAN devices to DTI under NAVSEA program - Ideal Power announced it delivered initial Bidirectional, Bipolar Junction Transistor, B-TRAN, devices to Diversified Technologies, DTI, under the contract awarded to DTI by the United States Naval Sea Systems Command, NAVSEA, to develop and demonstrate a B-TRAN enabled high efficiency 12kV medium voltage direct current, MVDC, circuit breaker. These initial devices will be utilized for characterization and testing to support DTI's breaker design efforts in advance of future device deliveries for incorporation into a full-scale MVDC circuit breaker. Prior to delivery, the B-TRAN devices were tested and demonstrated results consistent with the very low losses predicted by prior internal and third-party simulations. "The delivery of initial packaged B-TRAN devices to DTI is a significant accomplishment under the NAVSEA program. These devices incorporate the wafer processing improvements and packaging design developed under the program," said Dan Brdar, President and Chief Executive Officer of Ideal Power. "Circuit breakers perform a critical function in power generation, transmission, and distribution systems to protect against power surges and short circuits, with the circuit breaker market overall projected to grow at a compound annual growth rate of over 6% to approximately $26 billion by 2027, driven by the increased electrification of our daily lives. The fast-switching speed of B-TRAN solves the slow operating time and electrical arcing of traditional mechanical circuit breakers while also providing more than 50% lower conduction losses compared to solid-state circuit breakers utilizing conventional semiconductor power switches. These benefits position B-TRAN to potentially be an enabling technology for circuit breaker applications such as distributed direct current networks."

08:38 EDT Jack in the Box Q3 SSS down 0.6% - Systemwide sales for the third quarter decreased 1.4%. Same-store sales decreased 0.6% in the third quarter, comprised of a decline in franchise same-store sales of 1.0% and an increase in Company-operated same-store sales of 3.5%. Higher average check, driven mostly by pricing, was more than offset by traffic declines for franchise, and only partially offset by traffic declines for company-operated. The chicken and sides categories performed well, as did the snack and dinner day parts. During the quarter, systemwide sales declined relative to same-store sales due to a one-week shift affecting the calculation of same-store sales related to the 53rd week in 2021. This one-week shift had a more positive impact on same-store sales due to lapping less of the stimulus benefit in its calculation when compared to the fiscal quarter comparison.

08:35 EDT Safe-T secures up to $4M in strategic, non-dilutive funding - Safe-T Group announced the closing of a non-dilutive strategic funding agreement of up to $4,000,000 to support the further growth of its consumer privacy solutions and its customer acquisition program. Under the terms of the agreement, O.R.B. Spring will provide the Company with an upfront cash commitment of $2,000,000 with an additional $2,000,000 available subject to achievement of certain milestones. The funding, made through a series of cash installments until July 2023, will be allocated specifically towards Safe-T's customer acquisition program for one of its consumer privacy solutions. O.R.B. is controlled by Barak Avitbul, an accomplished technology industry entrepreneur and leader and the founder and former CEO of the Company's enterprise privacy business subsidiary, NetNut Ltd. The Company will repay the funding using a revenue share model that is based on sales generated only from customers of the new consumer privacy solution acquired with each funding installment. Each such funding installment shall be repaid within two years and if the repayments do not reach 100% of the installments, then the Company will cover the remaining amounts in cash or shares, at the Company's sole discretion. Once the investment amount has been repaid in full, Safe-T and O.R.B shall share the attributed revenue of the consumer privacy solution in equal parts until the lapse of five years after the date on which each installment was received by the Company. In addition, the investor was granted an opportunity to make additional investments in the Company through a series of warrants enabling him to increase his future interest in Safe-T's businesses, including the attractive consumer privacy market. The warrants will be exercisable at prices reflecting premiums ranging from approximately 130% to 300% of the current share price, for periods of up to 3 years from the vesting dates of the warrants. Upon potential exercise of all granted warrants, the Company may receive additional aggregate gross proceeds of between $2,000,000 and $4,000,000, based upon the amount of additional funding provided. The Company shall have the right to require the exercise of all or any portion of the warrants if the closing price of the Company's Ordinary Shares exceeds 150% of the respective exercise price of each series of warrants for three consecutive trading days. The Company has obtained an irrevocable undertaking from both O.R.B and Mr. Avitbul which includes a Grant of Irrevocable Proxy in connection to all voting rights attached to the Ordinary Shares of the Company underlying certain warrants or any shares issued for repayment. The undertaking shall solely apply in connection with certain voting matters and in accordance with the recommendations put forward to shareholders by the Board of Directors. The irrevocable undertaking will expire in regard to any shares sold by O.R.B. or Mr. Avitbul on a stock exchange market or upon the completion of a change of control.

08:34 EDT Aridis Pharmaceuticals' AR-701 cocktail shows anti-COVID protection in primates - Aridis Pharmaceuticals announced that inhaled treatment of its fully human monoclonal antibody cocktail AR-701 resulted in no detectable SARS-CoV-2 virus in the lungs of infected rhesus macaques, and protected their lungs from disease. AR-701 was effective in the non-human primates when used either as a prophylactic or therapeutic treatment regimen. Therapeutic administration of inhaled AR-701 substantially reduced and continued to suppress the viral load in the nasal sinus and oropharynx for the entire 5-day testing period. Additional lab research also indicates both mAbs in the AR-701 cocktail are effective against the SARS-CoV-2 Omicron BA.1, BA.2, BA.4, BA.5 subvariants in vitro. Preliminary study results were recently presented at the Immunotherapy for Infectious Diseases Conference 2022 in Pavia, Italy. Additional data are being analyzed and will be submitted to a peer-reviewed scientific journal for publication. AR-701 is a cocktail of two fully human immunoglobulin G1 mAbs discovered from screening the antibody secreting B-cells of convalescent SARS-CoV-2 - COVID-19 - infected patients.

08:31 EDT AIkido Pharma confirms receipt of unsolicited offer - AIkido Pharma confirms that on August 9, the company received an unsolicited offer from Shalom Auerbach to acquire all of the company's outstanding common stock for $8.00 per share in cash. The company's Board of Directors will carefully review the proposal to determine the course of action that it believes is in the best interest of the company and all AIkido shareholders. The company will respond in due course. There is no need for shareholders to take any action at this time.

08:24 EDT CAE lowers FY23 consolidated adjusted segment operating income growth view - For FY23, CAE now expects to deliver mid-20% consolidated adjusted segment operating income growth, from mid-30% previously, weighted more heavily to the second half of the year. Total capital expenditures are expected to be approximately $250M in FY23. On the revised outlook, CEO Parent stated, "we are lowering our outlook for the current fiscal year to mid-twenty percent consolidated adjusted segment operating income growth to account for the two U.S. program charges already incurred in Defense, and to reflect the more acute, sector-wide headwinds we are now experiencing, namely supply chain pressures, labour shortages, and a slower defence contracting environment. We previously indicated our expectation of a back-half-weighted performance in Defense this fiscal year, as we manage through the effects of a protracted period of less than one book-to-sales and begin to ramp up new orders in the second half. The additional Defense headwinds have made this weighting more pronounced, and we expect them to gradually abate through the course of the fiscal year. In our Civil business, we expect continued strong growth...For CAE overall, order intake remains a key leading indicator of our progress along the path to becoming a larger, more resilient, and more profitable company. We greatly enhanced our position and expanded our addressable market over the last couple of years, and I have complete confidence in our team's ability to maintain a strong order momentum and drive superior and sustainable growth and profits over the long-term. Broadly speaking, the underlying trendlines of our multi-year progress are very much intact, and my conviction in CAE's long-term growth outlook is resolute. We continue to target a three-year EPS compound growth rate in the mid-twenty percent range."

08:21 EDT Goodbody Health provides update on annual general, special meeting - Goodbody Health announces the results of the Company's Annual General and Special Meeting of the shareholders held on August 09, 2022. At the Meeting there were 77,050,554 shares represented in person or by proxy and voted, representing 21% of the total shares issued and outstanding. A majority of the shares were voted to accept the financial statements for the 2021 fiscal year. The shareholders unanimously voted to set the number of directors at six. The management nominations for directors, namely, Geremy Thomas, Marc Howells, Anne Tew, George Thomas, Clive Standish, and Mark Blower accepted their respective nominations as Directors of the Company. There were no nominations for directors from the floor. On the election of the directors, the percentage of votes cast for each director were as follows: Geremy Thomas - 99%; Marc Howells - 99%; Anne Tew - 99%; George Thomas - 99%; Clive Standish - 99%; Mark Blower - 98% In addition to the above, given the 99% approval from the shareholders that were represented at the Meeting, the vote exceeded the special resolution threshold of the required two-thirds of the outstanding shares of our common stock represented at the Meeting. As a result, the Company is pleased to announce its change of corporate jurisdiction to Guernsey from the Province of British Columbia, Canada by means of a process called a "continuation" under the Business Corporations Act has been approved and will be proceeded with. The Company will now file the required documents in Guernsey and British Columbia. Upon receipt of a certificate of continuation from the Registrar of Companies of British Columbia, the Company will no longer be a British Columbia corporation and will be governed by the laws of Guernsey. The change of corporate jurisdiction will not result in any material change to the business and will not have any effect on the relative equity or voting interests of shareholders. Each previously outstanding share of common stock will become one ordinary share of the Guernsey corporation. The continuation is currently anticipated to be effective on or about the 23rd of August 2022. The Company intends to delist from the CSE on or about Tuesday 16th August 2022 and trading is expected to be temporarily suspended on the AQSE on the same day. The 1 for 10 consolidation is expected to occur on or about Monday 22nd August. Trading is planned to resume on the AQSE on or about Tuesday 23rd August 2022 following the continuation.

08:18 EDT SAB Biotherapeutics expects cash to fund requirements for 12 months - Based on its current operating plans, SAB expects that its existing business plan, cash and cash equivalents, and anticipated cash flows as of June 30, 2022, will be sufficient to fund its operating expenses and capital expenditure requirements for the twelve months following the date our quarterly report on Form 10-Q was made available for issuance.

08:14 EDT Captura Biopharma to become public through OceanTech Acquisitions I merger - Captura Biopharma and OceanTech Acquisitions I announced that they have entered into a definitive business combination agreement that will result in Captura Biopharma becoming a publicly listed company. Upon closing of the transaction, OceanTech will be renamed Captura Biopharma and it expects to remain listed on Nasdaq. The combined company would have an approximate post-transaction equity market capitalization of $224.3M assuming a $10.00 per share price and no redemptions by OceanTech stockholders. The business combination has been approved by the boards of directors of both OceanTech and Captura Biopharma, and is expected to close in the fourth quarter of 2022, subject to review and approval by the U.S. Securities and Exchange Commission, regulatory and stockholder approvals and other customary closing conditions.

08:12 EDT FactSet appoints Kate Stepp as Chief Technology Officer - FactSet announced the appointment of Kate Stepp as Chief Technology Officer, CTO, effective September 1, 2022. Stepp will report directly to FactSet's CEO, Phil Snow. Stepp joined FactSet in 2008 and is currently Senior Director of Product Management within FactSet's Research and Advisory workflow solutions business. Stepp will succeed Gene Fernandez, who will continue with FactSet through November 2022 to ensure a smooth transition.

08:09 EDT BorgWarner secures second driver module award from Hyundai - BorgWarner's iDM146 integrated drive module has been selected by Hyundai Motor to power an additional A-Segment electric vehicle platform, scheduled to start production in 3Q24. This new business was awarded based on BorgWarner's iDM technology, its prior iDM win with HMC on another A-segment electric vehicle, and the previous relationship between the two companies.

08:08 EDT Outlook Therapeutics expects cash to fund operations into 1Q23 - At June 30, 2022, Outlook Therapeutics had cash and cash equivalents of $26.0 million. Outlook Therapeutics' cash and cash equivalents on hand are expected to provide funding into the first calendar quarter of 2023.

08:07 EDT Outlook Therapeutics announces anticipated milestones - Complete re-submission of BLA for ONS-5010 for the treatment of wet age-related macular degeneration; Receive Prescription Drug User Fee Act target action date from FDA; Continue progress with ongoing pre-launch commercial preparations in anticipation of potential approval for ONS-5010 in 2023; and Submission of Marketing Authorisation Application in EU for ONS-5010.

08:06 EDT Joby Aviation expands contract with U.S. Air Force's Agility Prime program - Joby Aviation announced an expansion of its existing contract with the U.S. Air Force's Agility Prime program that increases the contract's potential value by more than $45M. Building on more than five years of engagement with defense agencies, the expanded contract leverages Joby's years of research and technology development and will include new testing to evaluate Joby's advanced technologies. It brings the potential value of the total contract to more than $75 million.

08:05 EDT Lexagene Holdings shortens time MiQLab System needs to report result - LexaGene announces it has significantly shortened the time the System needs to report a result. The MiQLab System is designed for in-clinic use, requires less than a minute to initiate sample processing, and returns results on the presence of 10 different pathogens and 33 markers for antimicrobial resistance. The microfluidic system executes a complex series of scripts to complete three main tasks, namely sample preparation, PCR reaction assembly, and PCR amplification and reporting. Previously, these three tasks took 120 minutes to complete, and now can be completed in just 80 minutes. Steve Armstrong, LexaGene's COO stated, "LexaGene's mission has been to provide the highest quality data in the shortest time possible. Recent studies have shown the MiQLab System to generate very high-quality data, so we have now turned our attention to speeding up the System. My team evaluated each of the three tasks and has increased some efficiencies that have shaved ~40 minutes off the time required to generate a result. We are completing some additional validation tests before releasing these improvements to our customers, which we anticipate will happen over the next 4-6 weeks."

08:04 EDT Comtech appoints Ken Peterman as CEO - Comtech announced that its board of directors has appointed chairman Ken Peterman president and CEO, succeeding Michael Porcelain effective immediately. Porcelain has also resigned from Comtech's board of directors. Porcelain will be available to assist in the transition as needed. Peterman joined the Comtech board in May after the board initiated a national search process in January with the goal of deepening the board's industry experience and strengthening its executive leadership expertise.

08:03 EDT Tracon says IDMC for ENVASARC trial recommends proceeding as planned - TRACON Pharmaceuticals announced that the Independent Data Monitoring Committee for the ENVASARC pivotal trial has recommended that the trial proceed as planned following the review of three week safety data from more than 20 patients enrolled into the trial as of June 30, 2022. The safety data reviewed included data from more than 10 patients enrolled into cohort A of treatment with single agent envafolimab at 600 mg administered subcutaneously every three weeks and more than 10 patients enrolled into cohort B of treatment with envafolimab at 600 mg administered subcutaneously every three weeks with Yervoy given intravenously.

08:02 EDT Pacira reports preliminary net product sales of $50.2M for July - Pacira BioSciences reported preliminary unaudited net product sales of $50.2M for the month of July 2022. The company's net product sales include EXPAREL, ZILRETTA and the iovera system. The company began recognizing sales of ZILRETTA in November 2021 after completing its acquisition of Flexion Therapeutics, Inc. "We are pleased to report continued EXPAREL growth despite lingering market disruptions. This solid performance underscores expanding adoption as the market continues to recognize the significant advantages of EXPAREL-based opioid-sparing approaches for postsurgical pain," said Dave Stack, chairman and chief executive officer of Pacira BioSciences. "We are rolling out key partnerships that provide a clear pathway for expanding our customer base by supporting training and education around EXPAREL best-practice across multiple service lines. Our ZILRETTA franchise continues to perform well and remains in the early stage of its growth trajectory. In addition, the market feedback around our Generation-2 iovera degrees device continues to be positive and we remain confident the product will return to more robust growth as the year progresses. On the clinical front, we are working diligently to advance a pipeline of new growth opportunities with top line results for our two Phase 3 studies of EXPAREL as a lower extremity nerve block on track for the third and fourth quarters."

07:43 EDT Pipestone Energy sees 2024 production 46,000-48,000 boe/d

07:42 EDT Pipestone Energy confirms 2022 production view 31,000-33,000 boe/d - Pipestone is pleased to reconfirm its full year 2022 production guidance of 31,000 - 33,000 boe/d.

07:40 EDT Pipestone Energy sees Q3 production averaging 31,000-33,000 boe/d - During July 2022, which included 2 days of the planned turnaround at the Keyera Wapiti Gas Plant, corporate production averaged ~33,000 boe/d. During Q3 2022, the Company expects production to average 31,000 - 33,000 boe/d, which includes a 24-day planned turnaround at the Tidewater Gas Plant in September.

07:37 EDT ZW Data Action Technologies announces strategic cooperation with Nanyue - ZW Data Action Technologies announced that it entered into a letter of intent with Nanyue Health, owned by Guangdong Nanyue Pharmaceutical, pursuant to which the parties shall form a strategic partnership to jointly conduct marketing, share resources, jointly operate traffic and cooperate on other aspects of the Smart Medicine Cabinet Machine and Chan Li Chai Health Project. Pursuant to the letter of intent, the cooperation with Nanyue Health will be performed in two phases. ZW Data will provide the services which include market expansion and on-off line self-service machine smart service and Blockchain Technology in two phases. The Phase One includes business cooperation, sales of the smart medicine cabinet machines, and establishment of the operation team of Chan Li Chai Health Project for the offline market expansion. For Phase Two, the two parties will have technology cooperation on the platform of "Online Mall Service + Offline Smart Health Service Station + Blockchain Technology", including private domain traffic diversion, the establishment of operation and marketing service team, and expansion of private domain traffic service. "We are very excited about this cooperation, as the medical and health markets in China are full of potential in the future. This cooperation between the Company and Nanyue Health in the huge potential markets will help expand the Company's franchise business. Meanwhile, the big data technology and powerful channel resources of the Company will be a booster for this cooperation, promoting the innovative development of both parties in the field of big health. Going forward, the Company will continue to seek cooperation opportunities with leading enterprises in the field of big health to bring great returns to our shareholders in the future," commented Handong Cheng, Chairman and Chief Executive Officer of ZW Data.

07:35 EDT BridgeBio, Sentynl, Medison announce approval in Israel for NULIBRY - BridgeBio Pharma and Sentynl Therapeutics, along with partner Medison Pharma announced that the State of Israel Ministry of Health has approved NULIBRY for Injection as the first therapy in Israel to treat MoCD Type A with the indication to reduce the risk of mortality for patients with molybdenum cofactor deficiency Type A. MoCD Type A is an ultra-rare and progressive condition, known to impact less than 150 patients globally with a median survival of four years. NULIBRY is a cPMP substrate replacement therapy that was approved by the U.S. FDA in February 2021 to reduce the risk of mortality in patients with MoCD Type A. In July 2022 the CHMP recommended that NULIBRY be approved in the EU as a treatment for patients with MoCD Type A. Based on the CHMP recommendation, a decision by the European Commission, which authorizes marketing applications in the EU, is expected on the NULIBRY application later this year. The approval by the State of Israel Ministry of Health is supported by data from three clinical trials that demonstrated efficacy of NULIBRY for the treatment of patients with MoCD Type A compared to data from a natural history study. These studies showed that NULIBRY reduced the risk of death by 82% and increased the probability of survival to 84% at three years compared to 55% in the untreated, genotype-matched, historical control group in the natural history study. Animal studies have identified that NULIBRY has phototoxic potential. In the clinical trials, the most common adverse reactions reported in two or more NULIBRY-treated patients with MoCD Type A were catheter-related complications, pyrexia, viral infection, pneumonia, otitis media, vomiting and cough/sneezing. Adverse reactions for the rcPMP-treated patients were similar to the NULIBRY-treated patients.

07:33 EDT BridgeBio, Sentynl, Medison announce approval in Israel for Nulibry - BridgeBio Pharma, Sentynl Therapeutics, along with partner Medison Pharma, announced that the State of Israel Ministry of Health has approved Nulibry for Injection as the first therapy in Israel to treat MoCD Type A with the indication to reduce the risk of mortality for patients with molybdenum cofactor deficiency Type A. MoCD Type A is an ultra-rare and progressive condition, known to impact less than 150 patients globally with a median survival of four years.

07:25 EDT Stella-Jones 'remains confident' in three-year strategic guidance - Stella-Jones' sales are primarily to critical infrastructure-related businesses. While all product categories can be impacted by short-term fluctuations, the business is mostly based on replacement and maintenance-driven requirements, which are rooted in long-term planning. Corresponding to this longer-term horizon and to better reflect the expected sales run-rate for residential lumber and reduce the impact of commodity price volatility, the Company shifted its guidance to a three-year outlook in early 2022. Below are key highlights of the 2022-2024 outlook with a more comprehensive version, including management assumptions, available in the Company's MD&A. Management remains confident in the achievement of its three-year strategic guidance. Key Highlights: Compound annual sales growth rate in the mid-single digit range from 2019 pre-pandemic levels to 2024; EBITDA margin of approximately 15% for the 2022-2024 period; Capital investment of $90 to $100 million to support the growing demand of its infrastructure-related customer base, in addition to the $50 to $60 million of annual capital expenditures; Residential lumber sales expected to stabilize between 20-25% of total sales while infrastructure-related businesses expected to grow and represent 75-80% of total sales by 2024; Anticipated returns to shareholders between $500 and $600 million during three-year outlook period; Leverage ratio of 2.0x-2.5x between 2022-2024, but may temporarily exceed range to pursue acquisitions.

07:19 EDT Verano Holdings releases signature reserve, product line to four markets - Verano Holdings announced the Company now offers its namesake Verano signature flower branded products in four new core markets: Arizona, Florida, Massachusetts and Pennsylvania. Verano flower product offerings now available in the new markets include: Arizona: Verano Reserve and Essence flower, Swift Lift mini pre-roll packs, and vaporizers; Florida: Verano Reserve flower; Massachusetts: Verano Reserve and Essence flower, extracts, vaporizers and Swift Lift mini pre-roll packs; Pennsylvania: Verano Reserve and Essence flower, Live Resin cartridges, extracts and vaporizers. "The expanded footprint of Verano flower in four additional core markets demonstrates our ability to scale and meet market demand, serving more patients and consumers," said George Archos, Verano Founder and Chief Executive Officer. "With major medical cannabis communities in Florida and Pennsylvania, and large consumer bases in Massachusetts and Arizona, the growth of our brand portfolio highlights the increasing demand for high quality cannabis products across more than 100 of our own operating dispensaries and a growing wholesale distribution network."

07:17 EDT Miromatrix Medical appoints Lake as Medical Director - Miromatrix Medical announced that it has appointed Jack Lake, M.D. as the Company's new Medical Director. Dr. Lake is a Professor of Surgery and Medicine and the Chief of Hepatology in the Department of Medicine at the University of Minnesota. He is also the Executive Medical Director for Solid Organ Transplantation at the University of Minnesota Medical Center. Dr. Lake will serve as Miromatrix's Medical Director while remaining in his current roles at the University.

07:12 EDT Kornit Digital board authorizes $75M share repurchase authorization - The Company announced that its Board of Directors has authorized the repurchase of up to $75 million of the Company's ordinary shares, subject to the completion of required Israeli regulatory procedures.

07:10 EDT Gamida Cell doses first patient in GDA-201 study - Gamida Cell announced dosing of the first patient in a company-sponsored Phase 1/2 study evaluating a cryopreserved, readily available formulation of GDA-201 for the treatment of follicular and diffuse large B cell lymphomas.

07:08 EDT Canadian Solar subsidiary to build high-purity polysilicon facility in China - Canadian Solar announced that a wholly-owned subsidiary of its majority-owned subsidiary CSI Solar has entered into an investment agreement with the municipal government of Haidong City in Qinghai Province. Under the agreement, CSI Solar plans to build a facility with an annual capacity of approximately 50,000 tons of high-purity polysilicon later in 2022, as the initial project in an effort to build a solar manufacturing industrial park in Haidong. The facility is expected to commence production in mid-2024.

07:06 EDT Wendy's CEO says 'our business continued to outperform the competition' - "We are proud of the entire Wendy's system for delivering a third consecutive quarter of accelerating double digit Global same-restaurant sales on a two-year basis, which exceeded our expectations," President and CEO Todd Penegor said. "This momentum contributed to a significant sequential company-operated restaurant margin expansion, highlighting the strength of the underlying business and our brand as well as our commitment to the restaurant economic model in a challenging environment. Our business continued to outperform the competition and our franchisees are operating from a position of strength after achieving record profits across the US and Canada in 2021. This success drives alignment behind our commitment to deliver growth across our three strategic pillars and gives us confidence that we will achieve our vision of becoming the world's most thriving and beloved restaurant brand."

07:04 EDT Cullinan expects cash to fund operations through 2026 - Cash and investments were $656 million as of June 30, 2022. During the second quarter of 2022, we received cash proceeds of $270 million from the sale of Cullinan Pearl. The remaining $5 million of the $275 million upfront payment was held in escrow as of June 30 and is expected to be released in the third quarter of 2022. Based on current operating plans, the Company expects that its cash and investments will be sufficient to fund operations through 2026.

07:01 EDT Wendy's reports Q2 U.S. systemwide sales growth of 3.5% - Reports Q2 International systemwide sales growth 22.7%; Global 5.6%.

06:54 EDT Innoviz Technologies expects to increase order book by more than 30% in FY22 - The company said, "The Company expects to increase its order book by more than 30% by the end of fiscal year 2022. The Company has achieved its expected stated goal to secure 10 pre-production programs during 2022. To date, the Company has participated in 12. The Company currently has 12 prospective customers in at different RFI and RFQ stages. The Company expects to drive material revenue by the end of 2023 from previously announced series wins with BMW and an L4 autonomous shuttle program, as well as from non-automotive end markets."

06:47 EDT Lazard reports preliminary AUM $225.1B as of July 31 - The month's AUM included market appreciation of $9.8B, foreign exchange depreciation of $1B, and net outflows of $0.3B.

06:39 EDT DTE Energy to add 650 megawatts of new solar energy capacity for Ford - Through a new clean energy agreement with DTE Energy (DTE), Ford (F) will soon be able to attribute all its electricity supply in Michigan to clean energy, a major step toward Ford's goal to reach carbon neutrality. As part of the new agreement announced, DTE will add 650 megawatts of new solar energy capacity in Michigan for Ford by 2025. The purchase is a strategic investment in Michigan through DTE's MIGreenPower program and is the largest renewable energy purchase ever made in the U.S. from a utility. Since 2009, DTE's investments in renewable energy have created more than 4,000 Michigan jobs. DTE estimates that the construction of the solar arrays will create 250 temporary jobs and 10 permanent jobs. Local communities that host DTE's renewable energy projects also benefit from the additional tax revenue these projects generate.

06:36 EDT Centessa to discontinue development of ZF874 - The company announced its decision to discontinue development of ZF874 following a recent report of an adverse event involving elevated liver enzymes in a PiMZ subject dosed with 5 mg/kg BID of ZF874 in the Phase 1 study. ZF874, a pharmacological chaperone designed to rescue the folding of the Z variant of alpha-1-antitrypsin, was in a Phase 1 study for the treatment of AATD. As previously reported in November 2021, elevated liver enzymes were observed in a subject dosed with 15 mg/kg BID of ZF874 in the first cohort of patients within Part B of the Phase 1 study. Based on the results observed to date, the company concluded that ZF874 was unlikely to achieve the desired target product profile. Dr. Saha concluded, "While this is disappointing news for the A1AT patient community, we continue to believe that the pharmacological chaperone approach has the potential to address both the lung and liver manifestations of AATD. We are analyzing data from the Phase 1 study to help inform potential future development plans for our back-up compounds."

06:20 EDT Primo Water announces $100M share repurchase program - Primo Water announced that its board of directors authorized a new $100M share repurchase program and declared a quarterly dividend. The board of directors authorized a new $100M share repurchase program which commences on August 15 and expires on August 14, 2023. Under the program, the company's common shares may be repurchased periodically in open market or privately negotiated transactions through the facilities of the NYSE.

06:12 EDT ChipMOS reports July revenue $65.1M, up 19.4%

05:45 EDT Elon Musk says 'done' selling Tesla shares - Asked on Twitter if he was done selling Tesla (TSLA) shares, Elon Musk tweeted, "Yes." Musk added: "In the (hopefully unlikely) event that Twitter (TWTR) forces this deal to close *and* some equity partners don't come through, it is important to avoid an emergency sale of Tesla stock." Reference Link

05:35 EDT Tesla's 500 mile range Semi Truck starts shipping this year, Musk says - Elon Musk said via Twitter that Tesla's 500 mile range Semi Truck starts shipping this year and the Cybertruck next year. Reference Link

05:09 EDT Hyatt opens Magma Resort Santorini - Hyatt announced the opening of Magma Resort Santorini, the first property in The Unbound Collection by Hyatt brand in the Greek Islands. The opening signals Hyatt's continued focus on growing its brands within the Independent Collection in key, desirable global destinations for guests.